A U.S. appeals court on Monday invalidated Acorda Therapeutics Inc patents covering its multiple sclerosis drug Ampyra, opening the door to generic competition for the company's flagship product.Reuters Health Information (Source: Medscape Medical News Headlines)


Read full article on medworm.com